BI 456906 vs Mazdutide
Head-to-head comparison of BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | BI 456906 | Mazdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | N/A | ~5,000 Da |
| Half-Life | Approximately 1 week | 5-7 days |
| Amino Acids | N/A | 37 |
| Typical Dose | Trial-dependent; weekly SC dosing | 1-6 mg weekly in obesity trials |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 10 | 28 |
| Research Status | Clinical | Clinical |
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.